Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase - Carbonyl reductase 1

Chemico-Biological Interactions

Volumn 234, Issue , 2015, Pages 162-168

  Hintzpeter, Jan ^a   Hornung, Jan ^a   Ebert, Bettina ^a   Martin, Hans Jörg ^a   Maser, Edmund ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Anthracycline resistance; Carbonyl reductase 1; Cardiotoxicity; Curcumin; Daunorubicin; Tight binding inhibition

Indexed keywords

ALCOHOL DEHYDROGENASE; ALDEHYDE REDUCTASE; ANTINEOPLASTIC AGENT; CARBONYL REDUCTASE; CBR1 PROTEIN, HUMAN; CURCUMIN; DAUNORUBICIN; DAUNORUBICINOL; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANALOGS AND DERIVATIVES; BINDING SITE; HUMAN; METABOLISM; NEOPLASMS; TUMOR CELL LINE;

ALCOHOL OXIDOREDUCTASES; ALDEHYDE REDUCTASE; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CURCUMIN; DAUNORUBICIN; HUMANS; NADP; NEOPLASMS;

EID: 84933530924     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.12.019     Document Type: Article

References (68)

1. E. Schraufstatter, and H. Bernt Antibacterial action of curcumin and related compounds Nature 164 1949 456
2. S.C. Gupta, S. Prasad, J.H. Kim, S. Patchva, L.J. Webb, and I.K. Priyadarsini Multitargeting by curcumin as revealed by molecular interaction studies Nat. Prod. Rep. 28 2011 1937 1955 10.1039/c1np00051a
3. T. Esatbeyoglu, P. Huebbe, I.M.A. Ernst, D. Chin, A.E. Wagner, and G. Rimbach Curcumin - from molecule to biological function Angew. Chem. Int. Ed. Engl. 51 2012 5308 5332 10.1002/anie.201107724
4. M. Metzler, E. Pfeiffer, S.I. Schulz, and J.S. Dempe Curcumin uptake and metabolism BioFactors 39 2013 14 20 10.1002/biof.1042
5. SDR (short-chain dehydrogenases/reductases), (n.d.). http://www.sdr-enzymes.org/ (accessed August 11, 2014).
6. B. Wermuth Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase J. Biol. Chem. 256 1981 1206 1213
7. G.L. Forrest, and B. Gonzalez Carbonyl reductase Chem. Biol. Interact. 129 2000 21 40 10.1016/S0009-2797(00)00196-4
8. F. Hoffmann, and E. Maser Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily Drug Metab. Rev. 39 2007 87 144
9. P. Malatkova, E. Maser, and V. Wsol Human carbonyl reductases Curr. Drug Metab. 11 2010 639 658
10. B. Wermuth, K.L. Platts, A. Seidel, and F. Oesch Carbonyl reductase provides the enzymatic basis of quinone detoxication in man Biochem. Pharmacol. 35 1986 1277 1282
11. E. Maser, B. Stinner, and A. Atalla Carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung Cancer Lett. 148 2000 135 144
12. N. Kassner, K. Huse, H.J. Martin, U. Godtel-Armbrust, A. Metzger, and I. Meineke CBR1 is a predominant doxorubicin reductase in the human liver Drug Metab. Dispos. 2008 10.1124/dmd.108.022251
13. A. Slupe, B. Williams, C. Larson, L.M. Lee, T. Primbs, and A.J. Bruesch Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase Cardiovasc. Toxicol. 5 2005 365 376
14. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229 10.1124/pr.56.2.6
15. E. Barry, J.A. Alvarez, R.E. Scully, T.L. Miller, and S.E. Lipshultz Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management Expert Opin. Pharmacother. 8 2007 1039 1058 10.1517/14656566.8.8.1039
16. R.D. Olson, P.S. Mushlin, D.E. Brenner, S. Fleischer, B.J. Cusack, and B.K. Chang Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol Proc. Natl. Acad. Sci. U.S.A. 85 1988 3585 3589
17. G.L. Forrest, B. Gonzalez, W. Tseng, X. Li, and J. Mann Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice Cancer Res. 60 2000 5158 5164
18. A. Mordente, E. Meucci, G.E. Martorana, B. Giardina, and G. Minotti Human heart cytosolic reductases and anthracycline cardiotoxicity IUBMB Life 52 2001 83 88 10.1080/15216540252774829
19. D. Propper, and E. Maser Carbonyl reduction of daunorubicin in rabbit liver and heart Pharmacol. Toxicol. 80 1997 240 245
20. O.S. Bains, A. Szeitz, J.M. Lubieniecka, G.E. Cragg, T.A. Grigliatti, and K.W. Riggs A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin J. Pharmacol. Exp. Ther. 347 2013 375 387 10.1124/jpet.113.206805
21. S. Licata, A. Saponiero, A. Mordente, and G. Minotti Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction Chem. Res. Toxicol. 13 2000 414 420 10.1021/tx000013q
22. L.E. Olson, D. Bedja, S.J. Alvey, A.J. Cardounel, K.L. Gabrielson, and R.H. Reeves Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1 Cancer Res. 63 2003 6602 6606
23. B.J. Cusack, P.S. Mushlin, L.D. Voulelis, X.D. Li, R.J. Boucek, and R.D. Olson Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol. Appl. Pharmacol. 118 1993 177 185 10.1006/taap.1993.1023
24. M. Tanaka, R. Bateman, D. Rauh, E. Vaisberg, S. Ramachandani, and C. Zhang An unbiased cell morphology-based screen for new, biologically active small molecules PLoS Biol. 3 2005 10.1371/journal.pbio.0030128
25. Y. El-Hawari, A.D. Favia, E.S. Pilka, M. Kisiela, U. Oppermann, and H.-J. Martin Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis Chem. Biol. Interact. 178 2009 234 241 10.1016/j.cbi.2008.11.004
26. B. Ebert, M. Kisiela, V. Wsól, and E. Maser Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29 Chem. Biol. Interact. 191 2011 239 249 10.1016/j.cbi.2010.12.026
27. S. Fogli, R. Danesi, F. Innocenti, A. Di Paolo, G. Bocci, and C. Barbara An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma Ther. Drug Monit. 21 1999 367 375
28. H. Berman, K. Henrick, and H. Nakamura Announcing the worldwide Protein Data Bank Nat. Struct. Mol. Biol. 10 2003 10.1038/nsb1203-980 980-980
29. A. Grosdidier, V. Zoete, and O. Michielin SwissDock, a protein-small molecule docking web service based on EADock DSS Nucleic Acids Res. 39 2011 W270 W277 10.1093/nar/gkr366
30. A. Grosdidier, V. Zoete, and O. Michielin Fast docking using the CHARMM force field with EADock DSS J. Comput. Chem. 32 2011 2149 2159 10.1002/jcc.21797
31. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, and E.C. Meng UCSF Chimera - A visualization system for exploratory research and analysis J. Comput. Chem. 25 2004 1605 1612 10.1002/jcc.20084
32. J.F. Morrison Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors Biochim. Biophys. Acta 185 1969 269 286
33. J.W. Williams, and J.F. Morrison The kinetics of reversible tight-binding inhibition Methods Enzymol. 63 1979 437 467
34. R.A. Copeland Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis 2004 John Wiley & Sons
35. T. Matsunaga, S. Endo, M. Soda, H.-T. Zhao, O. El-Kabbani, and K. Tajima Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis Biochem. Biophys. Res. Commun. 389 2009 128 132 10.1016/j.bbrc.2009.08.107
36. O.S. Bains, T.A. Grigliatti, R.E. Reid, and K.W. Riggs Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin J. Pharmacol. Exp. Ther. 335 2010 533 545 10.1124/jpet.110.173179
37. A. Skarka, L. Škarydová, H. Štambergová, and V. Wsól Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase Chem. Biol. Interact. 191 2011 66 74 10.1016/j.cbi.2010.12.016
38. O.S. Bains, M.J. Karkling, J.M. Lubieniecka, T.A. Grigliatti, R.E. Reid, and K.W. Riggs Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism J. Pharmacol. Exp. Ther. 332 2010 755 763 10.1124/jpet.109.160614
39. O.S. Bains, M.J. Karkling, T.A. Grigliatti, R.E. Reid, and K.W. Riggs Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin Drug Metab. Dispos. Biol. Fate Chem. 37 2009 1107 1114 10.1124/dmd.108.024711
40. H. Ohara, Y. Miyabe, Y. Deyashiki, K. Matsuura, and A. Hara Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver Biochem. Pharmacol. 50 1995 221 227
41. E.S. Pilka, F.H. Niesen, W.H. Lee, Y. El-Hawari, J.E. Dunford, and G. Kochan Structural basis for substrate specificity in human monomeric carbonyl reductases PLoS ONE 4 2009 e7113 10.1371/journal.pone.0007113
42. R.H. Takahashi, O.S. Bains, T.A. Pfeifer, T.A. Grigliatti, R.E. Reid, and K.W. Riggs Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro Drug Metab. Dispos. Biol. Fate Chem. 36 2008 991 994 10.1124/dmd.108.020388
43. D.A. Dickinson, K.E. Iles, A.F. Wigley, and H.J. Forman Analysis of transcription factor remodeling in phase II gene expression with curcumin Methods Enzymol. 378 2004 302 318 10.1016/S0076-6879(04)78023-4
44. Y. Xie, Q.Y. Zhao, H.Y. Li, X. Zhou, Y. Liu, and H. Zhang Curcumin ameliorates cognitive deficits heavy ion irradiation-induced learning and memory deficits through enhancing of Nrf2 antioxidant signaling pathways Pharmacol. Biochem. Behav. 2014 10.1016/j.pbb.2014.08.005
45. B. Chen, Y. Zhang, Y. Wang, J. Rao, X. Jiang, and Z. Xu Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression J. Steroid Biochem. Mol. Biol. 143 2014 11 18 10.1016/j.jsbmb.2014.01.009
46. T. Miura, A. Taketomi, T. Nishinaka, and T. Terada Regulation of human carbonyl reductase 1 (CBR1, SDR21C1) gene by transcription factor Nrf2 Chem. Biol. Interact. 202 2013 126 135 10.1016/j.cbi.2012.11.023
47. W.-D. Chen, and Y. Zhang Regulation of aldo-keto reductases in human diseases Front. Pharmacol. 3 2012 35 10.3389/fphar.2012.00035
48. B.B. Aggarwal, and S. Shishodia Molecular targets of dietary agents for prevention and therapy of cancer Biochem. Pharmacol. 71 2006 1397 1421 10.1016/j.bcp.2006.02.009
49. B.B. Aggarwal, M.E. Van Kuiken, L.H. Iyer, K.B. Harikumar, and B. Sung Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis Exp. Biol. Med. Maywood NJ 234 2009 825 849 10.3181/0902-MR-78
50. A. Goel, A.B. Kunnumakkara, and B.B. Aggarwal Curcumin as "Curecumin": from kitchen to clinic Biochem. Pharmacol. 75 2008 787 809 10.1016/j.bcp.2007.08.016
51. S.S. Lakhman, X. Chen, V. Gonzalez-Covarrubias, E.G. Schuetz, and J.G. Blanco Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor Mol. Pharmacol. 72 2007 734 743 10.1124/mol.107.035550
52. T. Nabekura, S. Kamiyama, and S. Kitagawa Effects of dietary chemopreventive phytochemicals on P-glycoprotein function Biochem. Biophys. Res. Commun. 327 2005 866 870 10.1016/j.bbrc.2004.12.081
53. J. Abraham, N.N. Salama, and A.K. Azab The role of P-glycoprotein in drug resistance in multiple myeloma Leuk. Lymphoma 2014 1 8 10.3109/10428194.2014.907890
54. K. Ihlefeld, H. Vienken, R.F. Claas, K. Blankenbach, A. Rudowski, and M. Ter Braak Upregulation of ABC transporters contributes to chemoresistance of sphingosine-1-phosphate lyase-deficient fibroblasts J. Lipid Res. 2014 10.1194/jlr.M052761
55. S. Anuchapreeda, P. Leechanachai, M.M. Smith, S.V. Ambudkar, and P. Limtrakul Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells Biochem. Pharmacol. 64 2002 573 582
56. P. Limtrakul, W. Chearwae, S. Shukla, C. Phisalphong, and S.V. Ambudkar Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin Mol. Cell. Biochem. 296 2007 85 95 10.1007/s11010-006-9302-8
57. W.-D. Lu, Y. Qin, C. Yang, L. Li, and Z.-X. Fu Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo Clin. São Paulo Braz. 68 2013 694 701 10.6061/clinics/2013(05)18
58. G. Srivastava, and J.L. Mehta Currying the heart: curcumin and cardioprotection J. Cardiovasc. Pharmacol. Ther. 14 2009 22 27 10.1177/1074248408329608
59. Y. Sadzuka, M. Nagamine, T. Toyooka, Y. Ibuki, and T. Sonobe Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin Int. J. Pharm. 432 2012 42 49 10.1016/j.ijpharm.2012.04.062
60. N. Venkatesan Curcumin attenuation of acute adriamycin myocardial toxicity in rats Br. J. Pharmacol. 124 1998 425 427 10.1038/sj.bjp.0701877
61. N. Venkatesan, D. Punithavathi, and V. Arumugam Curcumin prevents adriamycin nephrotoxicity in rats Br. J. Pharmacol. 129 2000 231 234 10.1038/sj.bjp.0703067
62. A.V. Swamy, S. Gulliaya, A. Thippeswamy, B.C. Koti, and D.V. Manjula Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats Indian J. Pharmacol. 44 2012 73 77 10.4103/0253-7613.91871
63. H. Qian, Y. Yang, and X. Wang Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy Eur. J. Pharm. Sci. 43 2011 125 131 10.1016/j.ejps.2011.04.002
64. L. Hosseinzadeh, J. Behravan, F. Mosaffa, G. Bahrami, A. Bahrami, and G. Karimi Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc. 49 2011 1102 1109 10.1016/j.fct.2011.01.021
65. H. Wang, L. Hu, C. Li, J. Zhang, and T. Zhang Increase of therapeutic activity of doxorubicin by long circulating liposomes in combination with curcumin Pharm. - Int. J. Pharm. Sci. 66 2011 871 874 10.1691/ph.2011.1057
66. M. Plebuch, M. Soldan, C. Hungerer, L. Koch, and E. Maser Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes Cancer Lett. 255 2007 49 56 10.1016/j.canlet.2007.03.018
67. S. Varatharajan, A. Abraham, W. Zhang, R.V. Shaji, R. Ahmed, and A. Abraham Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia Eur. J. Clin. Pharmacol. 68 2012 1577 1586 10.1007/s00228-012-1291-9
68. H. Kaiserová, T. Šimůnek, W.J.F. van der Vijgh, A. Bast, and E. Kvasničková Flavonoids as protectors against doxorubicin cardiotoxicity: Role of iron chelation, antioxidant activity and inhibition of carbonyl reductase Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1772 2007 1065 1074 10.1016/j.bbadis.2007.05.002 1949